Sd. Rowley et al., Severe central nervous system toxicity associated with the infusion of cryopreserved PBSC components, CYTOTHERAPY, 1(4), 1999, pp. 311-317
Citations number
20
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Background: The infusion of PBSC or BM cells cryopreserved with DMSO is ass
ociated with frequent, but generally minor toxicity. The most severe toxici
ty is the rarely-occurring anaphylactic reaction. Neurological complaints,
other than headache, have rarely been reported, except after infusion of ve
ry large quantities of DMSO.
Methods: We performed a retrospective chart-review of patients who experien
ced severe neurological toxicity during the infusion of PBSC components dur
ing the period of September 1992 through June 1998.
Results: Ten patients developed severe neurological toxicity during, or sho
rtly after the infusion of PBSC components cryopreserved in DMSO. The PBSC
components were collected by standard apheresis procedures and concentrated
to an average nucleated cell concentration of 6.9 x 10(8) cells/mL (range,
0.8-12.9 x 10(8) cells/mL), mononuclear cell concentration of 2.1 x 10(8)
cells/mL (range, 0.2-6.8 x 10(8) cells/mL), and platelet concentration of 1
.1 x 10(9) platelets/mL (range, 0.2-4.8 x 10(9) platelets/mL) before cryopr
eservation in 10% DMSO and autologous plasma or HSA. On the day of infusion
, the patients were medicated with 50 mg of diphenhydramine and 250 mg of h
ydrocortisone. Most patients also receive 12.5 g of mannitol. Six patients
suffered seizures during the infusion. Three patients suffered syncope, or
severe encephalopathy without obvious seizure activity. One patient suffere
d a transient ischemic attack (TIA) shortly after the infusion. The infusio
ns were halted after these events occurred. The maximum amount of DMSO infu
sed to any of these patients before the onset of neurological event was 0.6
g/kg patient weight. Six patients received additional cryopreserved cells
on the same or following day, without recurrence of the neurological event.
Discussion: These 10 patients represent 0.9% of 1092 patients and 0.8% of 1
328 infusions of cryopreserved PBSC components during the time-interval stu
died. The cause(s) of these events is not obvious and may include the addit
ion of citrate anti-coagulant to the component after thawing and the high c
ell concentrations used for cryopreservation.